Drugs / Ferrous Lactate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06487299 | Jul 2024 → Jan 2026 overdue | iron deficiency anemia | The Second Hospital of Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05489952 | Sep 2022 → Feb 2025 | osteoporosis | He Qifei | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ferrous lactate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05489952 ↗ |
| Route | Oral | “oral ferrous lactate is added after discharge” NCT05489952 ↗ |